Outlook Therapeutics is dedicated to developing therapies for the preservation of vision. #OTLK #ophthalmology #retinadisease #wetAMD
Outlook Therapeutics, Inc.
Biotechnology Research
Cranbury, New Jersey 9,662 followers
ONS-5010: A uniquely positioned anti-VEGF therapy for wet AMD, DME and BRVO
About us
Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010 / LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab-vikg for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway.
- Website
-
http://www.outlooktherapeutics.com
External link for Outlook Therapeutics, Inc.
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Cranbury, New Jersey
- Type
- Public Company
- Founded
- 2011
Locations
-
Primary
7 Clarke Dr
Cranbury, New Jersey 08512, US
Employees at Outlook Therapeutics, Inc.
Updates
-
Stay in the loop! Be the first to know about our latest updates and announcements. Join us today! https://bit.ly/48ZjFXP #OTLK #Ophthalmology #RetinaDisease #WetAMD
-
#TuneInToday for our presentation at the Virtual Investor Closing Bell Event at 4 PM ET. Register here: https://bit.ly/4e2hsOj #OTLK #Ophthalmology #RetinaDisease #WetAMD
-
#DidYouKnow: The Anti-VEGF retina market of people living with wet AMD is 1.75 million in the US and 1.52 million in Europe. https://bit.ly/3AaYOEI #OTLK #Ophthalmology #RetinaDisease #WetAMD
-
#InCaseYouMissedIt: We were thrilled to announce that enrollment in our NORSE EIGHT clinical trial has already completed. We’re incredibly grateful for this exciting achievement. https://bit.ly/3XsbOiy #OTLK #wetAMD #ophthalmology #retinadisease
-
#HappeningTomorrow: Join us for our presentation at the Virtual Investor Closing Bell Event at 4 PM ET. Register now: https://bit.ly/4e2hsOj #OTLK #Ophthalmology #RetinaDisease #WetAMD
-
Our President and CEO, Russell Trenary, shares his confidence in the potential of ONS-5010. https://bit.ly/3XsbOiy #OTLK #wetAMD #ophthalmology #retinadisease
-
#MarkYourCalendars for our Virtual Investor Closing Bell Event on September 19th at 4pm ET! Don't miss out, register here: https://bit.ly/4e2hsOj #OTLK #Ophthalmology #RetinaDisease #WetAMD
-
Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series on Thursday, September 19th at 4:00 PM ET. https://bit.ly/3XHSLRk #wetAMD #ophthalmology #retinadisease
-
We are dedicated to developing therapies for the preservation of vision. Find out more here: https://bit.ly/46Hmqx0 #OTLK #Ophthalmology #RetinaDisease #WetAMD